In endometrial cancer, either mutated METTL14 or reduced METTL3 limits the expression of m6A. However, limited m6A activates the AKT signalling pathway and stimulates proliferation and tumorigenicity by decreasing the negative AKT regulator PHLPP2 and increasing the positive AKT regulator mTORC2 [139]. This evidence concerns the gene AKT1 and endometrial cancer.